BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A. Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther 2018;366:367-76. [PMID: 29891587 DOI: 10.1124/jpet.118.248120] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Guerdjikova AI, Romo-Nava F, Blom TJ, Mori N, McElroy SL. Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder. Contemp Clin Trials 2021;110:106587. [PMID: 34610482 DOI: 10.1016/j.cct.2021.106587] [Reference Citation Analysis]
2 Abad VC. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives. Nat Sci Sleep 2021;13:75-91. [PMID: 33531850 DOI: 10.2147/NSS.S245020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
3 Wang J, Li X, Yang S, Wang T, Xu Z, Xu J, Gao H, Chen G. Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: A meta-analysis from randomized controlled trials. Pharmacol Res 2021;167:105522. [PMID: 33667687 DOI: 10.1016/j.phrs.2021.105522] [Reference Citation Analysis]
4 Hu Y, Chen J, Li B, Zhang Z, Gridnev ID, Zhang W. Nickel‐Catalyzed Asymmetric Hydrogenation of 2‐Amidoacrylates. Angew Chem 2020;132:5409-13. [DOI: 10.1002/ange.201916534] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
5 Wang J, Yang S, Li X, Wang T, Xu Z, Xu X, Gao H, Chen G. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials. Sleep Med 2021;79:40-7. [PMID: 33472129 DOI: 10.1016/j.sleep.2020.12.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yahyaei H, Sharifi S, Shahab S, Sheikhi M, Ahmadianarog M. Theoretical Study of Adsorption of Solriamfetol Drug on Surface of the B12N12 Fullerene: A DFT/TD-DFT Approach. LOC 2021;18:115-27. [DOI: 10.2174/1570178617999200818104322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
7 Fabara SP, Ortiz JF, Anas Sohail A, Hidalgo J, Altamimi A, Tama B, Patel UK. Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review. Cureus 2021;13:e16095. [PMID: 34345566 DOI: 10.7759/cureus.16095] [Reference Citation Analysis]
8 Yang J, Gao J. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Review of Clinical Pharmacology 2019;12:723-8. [DOI: 10.1080/17512433.2019.1632705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Abad VC, Guilleminault C. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea. Expert Review of Respiratory Medicine 2018;12:1007-19. [DOI: 10.1080/17476348.2018.1541742] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP; TONES 3 Study Investigators. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. Am J Respir Crit Care Med 2019;199:1421-31. [PMID: 30521757 DOI: 10.1164/rccm.201806-1100OC] [Cited by in Crossref: 54] [Cited by in F6Publishing: 24] [Article Influence: 27.0] [Reference Citation Analysis]
11 Cuomo MC, Sheehan AH, Jordan JK. Solriamfetol for the Management of Excessive Daytime Sleepiness. J Pharm Pract 2021;:8971900211009080. [PMID: 33882756 DOI: 10.1177/08971900211009080] [Reference Citation Analysis]
12 Fietze I, Blum H, Grüger H, Käßner F, Maurer JT, Nilius G, Penzel T, Triché D, Arzt M. Diagnostik und Therapie der residualen Tagesschläfrigkeit bei Patienten mit therapierter obstruktiver Schlafapnoe. Somnologie 2021;25:99-109. [DOI: 10.1007/s11818-021-00305-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zomorodi K, Chen D, Lee L, Lasseter K, Marbury T. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. J Clin Pharmacol 2019;59:1120-9. [PMID: 30865315 DOI: 10.1002/jcph.1402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zomorodi K, Kankam M, Lu Y. A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food. Clinical Therapeutics 2019;41:196-204. [DOI: 10.1016/j.clinthera.2018.12.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
15 Dauvilliers Y, Shapiro C, Mayer G, Lammers GJ, Emsellem H, Plazzi G, Chen D, Carter LP, Lee L, Black J, Thorpy MJ. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial. CNS Drugs 2020;34:773-84. [PMID: 32588401 DOI: 10.1007/s40263-020-00744-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Hu Y, Chen J, Li B, Zhang Z, Gridnev ID, Zhang W. Nickel‐Catalyzed Asymmetric Hydrogenation of 2‐Amidoacrylates. Angew Chem Int Ed 2020;59:5371-5. [DOI: 10.1002/anie.201916534] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 13.5] [Reference Citation Analysis]
17 Lal C, Weaver TE, Bae CJ, Strohl KP. Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management. Ann Am Thorac Soc 2021;18:757-68. [PMID: 33621163 DOI: 10.1513/AnnalsATS.202006-696FR] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Videnovic A, Amara AW, Comella C, Schweitzer PK, Emsellem H, Liu K, Sterkel AL, Gottwald MD, Steinerman JR, Jochelson P, Zomorodi K, Hauser RA. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord 2021. [PMID: 34191352 DOI: 10.1002/mds.28702] [Reference Citation Analysis]
19 Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B, Sellers E. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. J Psychopharmacol 2018;32:1351-61. [PMID: 30269642 DOI: 10.1177/0269881118796814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
20 Gandhi KD, Mansukhani MP, Silber MH, Kolla BP. Excessive Daytime Sleepiness: A Clinical Review. Mayo Clin Proc 2021;96:1288-301. [PMID: 33840518 DOI: 10.1016/j.mayocp.2020.08.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Earl DC, Van Tyle KM. New pharmacologic agents for insomnia and hypersomnia. Curr Opin Pulm Med 2020;26:629-33. [PMID: 32890017 DOI: 10.1097/MCP.0000000000000722] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Vringer M, Kornum BR. Emerging therapeutic targets for narcolepsy. Expert Opin Ther Targets 2021;:1-14. [PMID: 34402358 DOI: 10.1080/14728222.2021.1969361] [Reference Citation Analysis]
23 Kim H, Cho JW. Narcolepsy, How do We Manage it? J Sleep Med 2020;17:1-10. [DOI: 10.13078/jsm.200006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
24 Emsellem HA, Thorpy MJ, Lammers GJ, Shapiro CM, Mayer G, Plazzi G, Chen D, Carter LP, Villa KF, Lee L, Menno D, Black J, Dauvilliers Y. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. Sleep Medicine 2020;67:128-36. [DOI: 10.1016/j.sleep.2019.11.1250] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
25 Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol 2019;85:359-70. [PMID: 30694576 DOI: 10.1002/ana.25423] [Cited by in Crossref: 69] [Cited by in F6Publishing: 44] [Article Influence: 34.5] [Reference Citation Analysis]
26 Marra S, Arnaldi D, Nobili L. The pharmacotherapeutic management of obstructive sleep apnea. Expert Opinion on Pharmacotherapy 2019;20:1981-91. [DOI: 10.1080/14656566.2019.1652271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Chandler P, Lee L, Schwab R. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep 2020;43:zsz220. [PMID: 31691827 DOI: 10.1093/sleep/zsz220] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 24.0] [Reference Citation Analysis]
28 Sijben HJ, van Oostveen WM, Hartog PBR, Stucchi L, Rossignoli A, Maresca G, Scarabottolo L, IJzerman AP, Heitman LH. Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors. Sci Rep 2021;11:12290. [PMID: 34112854 DOI: 10.1038/s41598-021-91700-7] [Reference Citation Analysis]
29 Dong W, Xu X, Ma H, Lei Y, Lin Z, Zhao W. Enantioselective Rh-Catalyzed Hydroboration of Silyl Enol Ethers. J Am Chem Soc 2021;143:10902-9. [PMID: 34254797 DOI: 10.1021/jacs.1c06697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Weaver TE, Drake CL, Benes H, Stern T, Maynard J, Thein SG, Andry JM Sr, Hudson JD, Chen D, Carter LP, Bron M, Lee L, Black J, Bogan RK. Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial. Ann Am Thorac Soc 2020;17:998-1007. [PMID: 32353246 DOI: 10.1513/AnnalsATS.202002-136OC] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
31 Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, Uguen M, Robert P, Lecomte JM, Schwartz JC, Finance O, Ligneau X. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol. Pharmacol Res Perspect 2021;9:e00855. [PMID: 34423920 DOI: 10.1002/prp2.855] [Reference Citation Analysis]
32 Schweitzer PK, Mayer G, Rosenberg R, Malhotra A, Zammit GK, Gotfried M, Chandler P, Baladi M, Strohl KP. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment. Chest 2021;160:307-18. [PMID: 33631141 DOI: 10.1016/j.chest.2021.02.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Pooventhiran T, Cheriet M, Bhattacharyya U, Irfan A, Puchta R, Sowrirajan S, Thomas R. Detailed Structural Examination, Quantum Mechanical Studies of the Aromatic Compound Solarimfetol and Formation of Inclusion Compound with Cucurbituril. Polycyclic Aromatic Compounds. [DOI: 10.1080/10406638.2021.1937238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Yin Z, Hu W, Zhang W, Konno H, Moriwaki H, Izawa K, Han J, Soloshonok VA. Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019. Amino Acids 2020;52:1227-61. [PMID: 32880009 DOI: 10.1007/s00726-020-02887-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
35 Barker EC, Flygare J, Paruthi S, Sharkey KM. Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns. Nat Sci Sleep 2020;12:453-66. [PMID: 32765142 DOI: 10.2147/NSS.S162762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
36 Markham A. Solriamfetol: First Global Approval. Drugs 2019;79:785-90. [DOI: 10.1007/s40265-019-01123-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
37 Javaheri S, Javaheri S. Update on Persistent Excessive Daytime Sleepiness in OSA. Chest 2020;158:776-86. [PMID: 32147246 DOI: 10.1016/j.chest.2020.02.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
38 El-Solh AA, Rudraraju A, Pasrija D, Bui H. Pharmacotherapy of residual excessive sleepiness among continuous positive airway pressure (CPAP) treated patients with sleep apnea. Expert Opin Pharmacother 2022;:1-10. [PMID: 35045769 DOI: 10.1080/14656566.2022.2029408] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chen Y, Blough BE, Murnane KS, Canal CE. The synthetic cathinone psychostimulant α-PPP antagonizes serotonin 5-HT2A receptors: In vitro and in vivo evidence. Drug Test Anal 2019;11:990-8. [PMID: 30845376 DOI: 10.1002/dta.2582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
40 Zaccara G, Bartolini E, Tramacere L, Lattanzi S. Drugs for patients with epilepsy and excessive daytime sleepiness. Epilepsy Behav 2021;124:108311. [PMID: 34534876 DOI: 10.1016/j.yebeh.2021.108311] [Reference Citation Analysis]
41 Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs 2020;34:9-27. [PMID: 31953791 DOI: 10.1007/s40263-019-00689-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
42 Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109. [PMID: 32032921 DOI: 10.1016/j.sleep.2019.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
43 Dye TJ, Simakajornboon N. Narcolepsy in Children: Sleep disorders in children, A rapidly evolving field seeking consensus. Pediatr Pulmonol 2021. [PMID: 34021733 DOI: 10.1002/ppul.25512] [Reference Citation Analysis]
44 Zomorodi K, Chen D, Lee L, Swearingen D, Carter LP. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. Clin Pharmacol Drug Dev 2021;10:404-13. [PMID: 32935460 DOI: 10.1002/cpdd.867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Köteles I, Foroughbakhshfasaei M, Dobó M, Ádám M, Boldizsár I, Szabó Z, Tóth G. Determination of the Enantiomeric Purity of Solriamfetol by High-Performance Liquid Chromatography in Polar Organic Mode Using Polysaccharide-Type Chiral Stationary Phases. Chromatographia 2020;83:909-13. [DOI: 10.1007/s10337-020-03911-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Holst SC, Werth E, Landolt HP. [Pharmacotherapy of Sleep-Wake Disorders]. Praxis (Bern 1994) 2019;108:131-8. [PMID: 30722734 DOI: 10.1024/1661-8157/a003189] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Rameau A, Hong RS, Djalilian H, Erbele ID, Phillips KM, Capasso R, Rose AS, Brenner MJ, Santa Maria PL. New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2019. OTO Open 2020;4:2473974X20932506. [PMID: 32537556 DOI: 10.1177/2473974X20932506] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]